Article
AstraZeneca, Amgen tout PhIII win for 'breakthrough' asthma drug, checking a blockbuster box that D
Rating:
0.0
Views:
141
Likes:
1
Library:
1
A closely watched “breakthrough” asthma drug has hit all the right notes in a Phase III, AstraZeneca and Amgen say, paving the way to reach a currently untapped patient population. We're not getting much beyond the announcement that tezepelumab met the primary endpoint, but execs' enthusiastic comments suggest that what
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value